author-photo

Ja Ledermann

Charing Cross Hospital

80

Papers

1569

Citations

Citation Trend

Filter By

Papers (57) Sort By

Journal Conference Others

Correction to: “Safety and dose modification for patients receiving niraparib”

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Patterns of Recurrence and Survival in the Randomized Portec-3 Trial of Chemoradiotherapy for High-Risk Endometrial Cancer

2019 International Journal of Radiation Oncology Biology Physics
Show All
- Source
- Cite
- Save
Citations (0)
The effect of age on efficacy and safety outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase III, randomized, placebo-controlled maintenance study in patients with recurrent ovarian carcinoma

2019 Gynecologic Oncology
Show All
- Source
- Cite
- Save
Citations (2)
PCN295 PATIENT-CENTERED OUTCOMES IN ARIEL3, A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF RUCAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH RECURRENT OVARIAN CARCINOMA

2019 Value in Health
Show All
- Source
- Cite
- Save
Citations (10)
Corrections to “Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (54)
EFFECT OF PRIOR BEVACIZUMAB THERAPY IN PATIENTS WITH PLATINUM-SENSITIVE RECURRENT OVARIAN CARCINOMA (ROC) IN THE PHASE 3 STUDY ARIEL3

2018 International Journal of Gynecological Cancer
Show All
- Source
- Cite
- Save
Citations (0)
LBA41A double-blind, placebo-controlled, randomized, phase 2 study to evaluate the efficacy and safety of switch maintenance therapy with the anti-TA-MUC1 antibody PankoMab-GEX after chemotherapy in patients with recurrent epithelial ovarian carcinoma

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (8)
929O_PR ICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: results of primary progression- free survival (PFS) analysis

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (32)
965PEvaluation of tumour responses and olaparib efficacy in platinum-sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21)

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (7)
932PDEfficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: Phase III SOLO2 trial (ENGOT Ov-21)

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (3)